PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1392016
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1392016
Global radioactive tracer market size is expected to reach US$ 5.26 Bn by 2030, from US$ 3.24 Bn in 2023, exhibiting a CAGR of 7.2% during the forecast period.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 3.24 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 7.20% | 2030 Value Projection: | US$ 5.26 Bn |
Radioactive tracers have become an essential tool in several industries including healthcare, research, and oil exploration. These tracers consist of radioactive substances that emit radiation, which can be easily detected and measured. These are used to track the movement of specific molecules, study various biological processes, and identify potential sources of underground reserves. The global radioactive tracer market has witnessed significant growth in recent years, owing to increasing applications of radioactive tracers in medical diagnostics and treatment, and in the environmental and petrochemical sectors.
Global radioactive tracer market growth is driven by several factors including technological advancements, increasing prevalence of chronic diseases, and growing demand for personalized medicine. The market is witnessing significant growth due to rising adoption of diagnostic imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) that utilize radioactive tracers to detect and analyze various diseases and conditions.
The market faces certain challenges such as stringent regulations related to the use and disposal of radioactive substances. Regulatory bodies impose strict guidelines to ensure the safe handling and disposal of radioactive tracers, wand this significantly increases the cost of production and affects the market growth. The limited availability of skilled professionals and the high cost associated with nuclear medicine procedures are expected to restrain the market growth.
Despite these challenges, global radioactive tracer market is filled with opportunities for growth. Advancements in radiopharmaceutical manufacturing techniques and the development of new radioactive isotopes are expected to create new opportunities for market players. Moreover, increasing adoption of radioactive tracers in industries such as oil and gas exploration, environmental monitoring, and industrial testing is expected to drive the market growth further.
For instance, on March 16, 2023, Telix Pharmaceuticals Limited., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved a supplementary New Drug Application (sNDA) for Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) to enable patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is indicated.